Samsung Bioepis, Boryung Partner on Bone Disorder Biosimilar ‘Exbrick’

작성일 07-02

<strong class="summary_view" data-translation="true">Expanding product portfolio in Korea with Exbrick, following Onbevzi and Samfenet</strong> 
        <div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
         <section dmcf-sid="YQgIiNVZSh">
          <p contents-hash="4f87056a2785b36f0b13ee11caf8a6ed3ad0dbc4382e8b4d6b186cd9b770f8ee" dmcf-pid="GxaCnjf5TC" dmcf-ptype="general"> [Kim Saemi, Edaily Reporter] Samsung Bioepis announced on July 2 that it has signed a domestic partnership agreement with Boryung for the sales of ‘Exbrick,’ a biosimilar referencing Xgeva, a treatment for bone disorders.</p>
          <figure class="figure_frm origin_fig" contents-hash="cf1027e82ee2bc68bf29b9009274185fca666db3b23e6ce1e4bf263dd98b3e71" dmcf-pid="HMNhLA41SI" dmcf-ptype="figure">
           <p class="link_figure"><img alt="CI of Samsung Bioepis and Boryung (Source: Both Companies)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/02/Edaily/20250702215939572cvtf.jpg" data-org-width="525" dmcf-mid="WcsXDIJqll" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/02/Edaily/20250702215939572cvtf.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            CI of Samsung Bioepis and Boryung (Source: Both Companies)
           </figcaption>
          </figure>
          <div contents-hash="4d73599d9dcb66e9e4638513cc9bfa234723725ae11c1faa363664021fcfb965" dmcf-pid="XRjloc8tSO" dmcf-ptype="general">
           Under the agreement, Samsung Bioepis, as the developer, will be responsible for manufacturing and supplying Exbrick, while Boryung will take charge of exclusive domestic sales and marketing.
          </div>
          <p contents-hash="8fb06f01b23b0a63c373062081965c5a2b04c2d3bc9d07073c2aee0d3b69f495" dmcf-pid="ZeASgk6FSs" dmcf-ptype="general">Xgeva, developed by Amgen, is indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases and for the treatment of giant cell tumor of bone. As of 2024, its global sales reach approximately 3.3 trillion KRW.</p>
          <p contents-hash="4a9a3c765bd9df4859a701c193d105258ecd515cad144131cb9626240fa196ef" dmcf-pid="5fJwMnBWWm" dmcf-ptype="general">Through this agreement, Samsung Bioepis and Boryung are expanding their domestic biosimilar partnership portfolio to include Exbrick, following their collaboration on the oncology biosimilars Onbevzi (Avastin biosimilar) and Samfenet (Herceptin biosimilar), thereby strengthening their strategic alliance.</p>
          <p contents-hash="b7a6105a73b9ccbb9937d0c09b014f230e36d99977f31a0705839ae9a764cdbe" dmcf-pid="14irRLbYCr" dmcf-ptype="general">The partnership products have shown strong growth momentum. For instance, Onbevzi recorded sales of 45.2 billion KRW last year.</p>
          <p contents-hash="abe87ef51fedd197209e8fe4892c92df01a188ee3e3306d00501dd077af8963b" dmcf-pid="t8nmeoKGlw" dmcf-ptype="general">Boryung, which holds the top domestic market share among Korean pharmaceutical companies in oncology, operates the country’s largest specialized sales force and offers a wide range of therapeutic options, from supportive oncology medications to biosimilars.</p>
          <p contents-hash="2578a1f92ccaaeaaad518dfb95f912184a98b99eceec622bb87b21308e34ae25" dmcf-pid="F6Lsdg9HWD" dmcf-ptype="general">Samsung Bioepis obtained domestic marketing approval for Exbrick in May and had previously secured approval in the U.S. and Europe this February.</p>
          <p contents-hash="2eeb0d5e26a9174d2b1c7a4482281f1d2b5540404a7e249894049433e6c0f1dc" dmcf-pid="3PoOJa2XhE" dmcf-ptype="general">Kyung-Ah Kim, CEO of Samsung Bioepis, stated, “We will work closely with Boryung to expand treatment access through biologics for more patients in Korea, leveraging our product capabilities and Boryung’s commercial strength.”</p>
          <p contents-hash="7025e930c7b7cb89e6d67609fef4dcd8eb01abe8a696bd9e92c6564d8d88b4c7" dmcf-pid="0QgIiNVZCk" dmcf-ptype="general">Jung-Kyun Kim, CEO of Boryung, added, “We are pleased to add another high-quality biosimilar developed by Samsung Bioepis to our portfolio. Based on the proven synergy from our existing partnerships, we will do our utmost to ensure Exbrick gains early traction in the market.”</p>
          <p contents-hash="10c290077bd16c24d13e6ec861306987c964be27810dc0716bfd1caf2faf0c70" dmcf-pid="pxaCnjf5Sc" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p>
         </section> 
        </div> 
        <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>

이전

이효리, ♥이상순과 신혼같은 서울 생활 “비밀 연애 때는 같이 못 돌아다녀”(유퀴즈)

07-02
다음

올림픽 금메달리스트 반효진, 짜릿한 역전 우승!

07-02

등록된 댓글이 없습니다.

로그인한 회원만 댓글 등록이 가능합니다.

먹튀폴리스

Samsung Bioepis, Boryung Partner on Bone Disorder Biosimilar ‘Exbrick’

멤버랭킹

관련자료

멤버랭킹